Breast Cancer
Myth or Truth? Avoid Soy If You Have a Hormone-Positive Cancer
Editor’s Note: Patient Worthy is pleased to bring you this article, originally shared with us by our friend Julie Lanford, The Cancer Dietitian. To see
VIS-101 Demonstrates Favorable Safety and Early Efficacy in Wet AMD
- March 23, 2026
Jenny Decker’s Journey: An Update
Imfinzi Achieves European Milestone: First Immunotherapy to Improve Survival in Early Gastric Cancer
New Pain Medicine Seeking FDA Approval
LISTEN TO OUR PODCAST
THE LATEST FROM PATIENT WORTHY
Breast Cancer
Breaking New Ground: FDA Green-Lights Novel Breast Cancer Treatment Targeting Treatment-Resistant Tumors
The landscape of advanced breast cancer treatment is shifting. Genentech’s filing acceptance of giredestrant, an experimental oral medication, represents a pivotal moment for thousands of
Huntington's disease
Vico Therapeutics Begins Twice‑Yearly Dosing of VO659 in Phase 1/2 Trial for Huntington’s Disease and Spinocerebellar Ataxias
As reported in Business Wire, Vico Therapeutics has initiated patient dosing in an expanded cohort of its Phase 1/2a clinical study evaluating VO659, an antisense
Myelofibrosis
James’ Story: Navigating Life With Myelofibrosis
Editor’s Note: This article was shared with us by our friends at Heal Canada. To see the article in its original format, please click here.
Chronic Lymphocytic Leukemia
FDA Approves Revolutionary Oral Combination Therapy for Chronic Lymphocytic Leukemia, Offering Patients Freedom from Long-Term Treatment
AbbVie has announced a landmark regulatory milestone with the US FDA’s approval of a supplemental new drug application (sNDA) for the combination of Venclexta (venetoclax)
Rare Disease
First Patient Dosed in Phase 3 CLARITY Trial Evaluating Solriamfetol for MDD With Excessive Daytime Sleepiness
As published in Sleep Review Magazine, Axsome Therapeutics has officially begun dosing patients in its Phase 3 CLARITY trial, a study designed to evaluate solriamfetol
Fibrosis
Breaking the Fibrosis Barrier: How Fibrocor Therapeutics Is Revolutionizing Kidney Disease Treatment
Fibrosis, the accumulation of scar tissue in organs, disrupts normal organ function and leads to progressive impairment. Currently, there is no cure, and existing treatments
Diabetes Type 1
A New Chapter in Diabetes Care: Inside-the-Body Technology Breaks Ground
The relationship between people with type 1 diabetes and their medication has always been complicated. For decades, managing the condition has required constant vigilance including
Huntington's disease
Harness Therapeutics Advances First‑in‑Class Huntington’s Disease Candidate HRN001 and Forms Expert Clinical Advisory Board
As reported on PharmaBiz, Harness Therapeutics has selected HRN001 as its lead therapeutic candidate for Huntington’s disease (HD), marking a major milestone for the company
Rare Disease
Life Impact of Pain – Pain Series Part 2 of 3
Click here to see Part 1 of of this 3 part pain series. If you suffer with chronic pain, you not only live with the unrelenting
Obesity
Monthly Obesity Treatment Gets Easier: Lilly’s New Zepbound Pen Simplifies Weight Loss Injections
Patients using Zepbound for weight management now have a simpler option for administering their medication. As reported by PharmaLive.com, Eli Lilly received FDA clearance for
Prostate Cancer
Redefining Cancer Treatment: Podcast Interview with Dr. Charles Link on Sync-T and the Future of Immunotherapy
On this episode of Wait, How Do You Spell That?, host Bree Clare sits down with Dr. Charles Link, a pioneering oncologist whose career has
Bladder cancer
“At 44, I Thought I Was Starting Over” – Kristian’s Bladder Cancer Story
At 44 years old, I was ready to hit the reset button. In March of 2025, my partner and I stepped away from our careers.
Ovarian Cancer
British Columbia Researchers Develop a System to Reduce Ovarian Cancer by 80%
Ovarian cancer is a serious gynecological cancer with no reliable screening test, resulting in limited treatment options and a low number of survivors. Each year
Fibrodysplasia Ossificans Progressiva (FOP)
Breakthrough in Rare Bone Disease: FDA Fast-Tracks Garetosmab for Fibrodysplasia Ossificans Progressiva
Regeneron Pharmaceuticals announced that the U.S. Food and Drug Administration has accepted for Priority Review the Biologics License Application (BLA) for garetosmab, marking a significant
Datroway Receives U.S. Priority Review for First‑Line Treatment of Metastatic Triple‑Negative Breast Cancer
AstraZeneca and Daiichi Sankyo’s antibody‑drug conjugate Datroway (datopotamab deruxtecan) has been granted Priority Review by the U.S. Food and Drug Administration (FDA) for use as
Urea cycle disorders
More Than a Diagnosis: Gabriela’s Journey With Lysinuric Protein Intolerance, Urea Cycle Disorder, and Unshakable Faith
As a little girl, I believed miracles only existed in movies. They felt distant, beautiful stories meant for someone else. I never imagined that my
Psoriasis
Dual Approach to Disease: Eli Lilly’s Zepbound-Taltz Combination Demonstrates Breakthrough Results in Psoriasis Treatment
Eli Lilly is making strategic moves to expand its obesity medication Zepbound beyond weight management, demonstrating promising results when combined with its autoimmune therapeutic Taltz
FEATURED
UPCOMING EVENTS
SIGN UP FOR OUR NEWSLETTER
Common HIV myths—and the facts that debunk them. Swipe to learn the truth about transmission, treatment, and living with HIV. Share to fight stigma and spread accurate information. Share your story with us here: bit.ly/4dV7gru
#hivawareness #HIV #endthestigma #PatientWorthy #shareyourstory
Jenny Decker's Journey: An Update bit.ly/40GsVhr. Read now at PatientWorthy.com
#PatientWorthy #charcotmarietoothdisease #CMT #PatientStory #jennydecker
Cure GRIN FoundationThe countdown to Virtual GRICON26 is ON!
We’ve built this year’s agenda to bridge the gap between lab research and your daily GRI life. Best of all? Registration is pay what you can! What’s in store:
🔬 Clinical Updates: Phase 3 breakthroughs from industry leaders.
🏠 Living GRI: IEP advocacy, behavior management, and adulthood transitions.
🚀 The Next Frontier: Deep dives into ASOs and genetic therapies.
🤝 Community: Dedicated networking for families and siblings.
Your Saturday, Your Way: Customize your day with breakout sessions that matter most to your journey. HUGE thanks to our Diamond Sponsor, GRIN Therapeutics!
🔗 Register & View Agenda: bit.ly/49nBinf
❤️ Support the Journey
Want to honor a loved one? Become a Family Sponsor! While GRICON is free to attend, your sponsorship ensures a world class experience and fuels the research collaborations our community needs.
✨ Become a Family Sponsor: bit.ly/4sPm3Ks
#GRICON26 #GRIfamily #CureGRIN #RareDisease
